Publications
- Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma2018 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Pacientka s NSCLC léčeným ve druhé linii pembrolizumabemi2017 | Publication without faculty affiliation
- New treatment options for ALK-positive patients with NSCLC krizotinibem2016 | Publication without faculty affiliation
- Present and new trends in the treatment of non-small cell lung cancer2016 | Publication without faculty affiliation
- Current recommendations for the treatment of non -small-cell lung cancer with special focus to therapy of advanced NSCLC according to ESMO and NCCN guidelines and Blue Book2015 | Publication without faculty affiliation
- New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic2012 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Current therapeutic options for advanced/metastatic non-small cell lung cancer2011 | Publication without faculty affiliation
- Pemetrexed2009 | Publication without faculty affiliation
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
Loading network view...
